Updated: Outpatient COVID-19 treatments available in Ohio and Florida

Updated: Outpatient COVID-19 treatments available in Ohio and Florida

A Cleveland Clinic enterprise team is working on strategies for the equitable distribution and delivery of COVID-19 treatments.

Please see below for current treatments as well as Emergency Use Authorizations (EUA) and U.S. Food and Drug Administration (FDA) approval status for anti-viral and preventative therapies.

All COVID-19 therapies listed below are purchased by the federal government and distributed by state health departments with extremely limited allocation. Availability and appointments are limited.

New long-acting monoclonal antibodies for pre-exposure prevention of COVID-19: Evusheld

The FDA issued an EUA for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together by intramuscular injection) for the prevention of COVID-19 in certain high-risk adults and children 12 years of age and older, weighing at least 88 pounds.

Ohio:
Cleveland Clinic will be administering this to patients with the highest risk in certain subspecialty clinics on main campus in Ohio through scheduled appointments beginning Jan. 18, 2022.

Our specialty clinics will actively reach out to eligible patients to schedule appointments.

Additionally, the product is only authorized for patients who meet both of the following requirements:

  1. Patients who are not currently infected with COVID-19 and
  2. Patients who have not recently been exposed to an individual infected with COVID-19.

Patients will require documentation of a negative COVID-19 test at least three days before their scheduled injection.

Primary care providers as well as patients can reach out to a patient’s specialty provider with any questions.

Florida:

Cleveland Clinic locations in Florida have not received allocations of Evusheld. We will provide ongoing allocation and distribution updates for these therapies.

Oral antiviral agents for COVID-19: Paxlovid and Molnupiravir

Paxlovid (nirmatrelvir and ritonavir) and Molnupiravir received EUA approvals last December. These oral antivirals treat mild to moderate COVID-19 infection in high-risk outpatients.

Paxlovid can be used for adults and children at least 12 years of age and at least 88 pounds.

Molnupiravir is only approved for adults 18 years and older and should not be used in pregnant or lactating women.

Ordering criteria

The oral antivirals are EUA-approved for outpatients who meet all three of the following requirements:

  1. Test positive for COVID-19
  2. Are within five days of symptom onset
  3. Are at high risk for progression to severe COVID-19, which includes hospitalization

Ohio:

Cleveland Clinic began distribution of Paxlovid and Molnupiravir in January.

  • Patients: Patients should contact their primary care providers to review the EUA fact sheet and determine eligibility.
  • Prescribers: Prescribers can find details on the therapies and patient eligibility criteria at this link.

How to order

Prescribers must use the SmartSet in Epic called COVID-19 Oral Therapies. This SmartSet is the only way to order COVID oral antivirals at Cleveland Clinic. It includes product availability details and ordering instructions.

Cleveland Clinic Emergency Departments in Northeast Ohio do not provide outpatient COVID therapies including monoclonal antibody infusions and prescriptions for oral therapies. These therapeutics cannot be ordered by emergency department providers.

Florida:

Cleveland Clinic locations in Florida have not received allocations of Paxlovid or Molnupiravir. We will provide ongoing allocation and distribution updates for these therapies.

Monoclonal antibody infusions for treatment of mild to moderate COVID-19: Sotrovimab

Cleveland Clinic provides monoclonal antibody infusions to treat mild to moderate COVID-19 infection in certain patients who have a high risk for severe illness. The demand for COVID-19 monoclonal antibody infusions outweighs the supply of infusion appointments.

In Northeast Ohio, we offer outpatient COVID-19 monoclonal antibody infusions at three locations*:

  • Marymount Hospital, adults
  • Akron General Health and Wellness Center located at Green, the preferred location for adults with immunocompromising disorders and therapies
  • Main campus R building, pediatrics only

In Florida, we offer outpatient COVID-19 monoclonal antibody infusions at the following locations:

  • Outpatient infusion sites: Martin North, Weston
  • ED infusion sites: Indian River

Cleveland Clinic’s monoclonal antibody appointments are for patients who are under the care of a Cleveland Clinic primary care provider or select sub specialty provider. Patients should contact their primary care provider or subspecialty provider to determine if they are a candidate for an infusion.

There are additional locations throughout Ohio and Florida that offer COVID-19 monoclonal antibody infusions. Click here using Google Chrome to view an interactive map.

For the latest information on COVID-19 monoclonal antibody therapeutics, click here.

Quick reference guide:

COVID-19 Treatment Type Clinical Criteria Risk Locations
Paxlovid and Molnupiravir Oral antiviral Mild to moderate COVID-19 infection High-risk outpatients Ohio only; not available through any Cleveland Clinic Emergency Departments
Sotrovimab Monoclonal antibody infusions Mild to moderate COVID-19 infection High-risk outpatients Ohio and Florida; limited locations*
Evusheld Monoclonal antibody intramuscular injection Pre-exposure prevention of COVID-19 Highest risk in certain subspecialty clinics Ohio only; certain subspecialty clinics on main campus
Travel and event policies remain the same for all caregivers

Travel and event policies remain the same for all caregivers

As the pandemic evolves, we continually assess our travel policies while prioritizing the safety of our patients and caregivers.

Please note that our most recent guidelines related to business travel and hosting events provided in 2021 are still in effect. We will continue to monitor this situation and re-evaluate these guidelines at the end of Q1 2022.

This means that work-related travel opportunities continue to be permitted in a limited capacity, as described below, for all caregivers. It also means that our policy regarding in-person, on-site and off-site events hosted by Cleveland Clinic remains the same.

Work-related travel opportunities

Caregivers are often invited to speak at professional conferences or meetings. When you speak to others in your field as Cleveland Clinic caregivers, you help extend our academic mission and promote our brand. These are also enriching professional experiences.

If you are invited to speak at events as a representative of Cleveland Clinic, you may be eligible to travel. The decision to travel still requires approval by your Institute Chair, Hospital President or Executive Team member, as appropriate.

As part of the approval process, please also provide written documentation that validates your speaking engagement, such as a confirmation email from the inviting association.

Once leadership approves and it is time to book your trip, please send all approval documentation referenced above, as well as an email or other support information showing that leadership has approved, to GBTclinictravel@amexgbt.com.

Please note that this includes both domestic and international travel in adherence with local, state, national or international guidelines related to the pandemic.

What about other travel requests?

All other meeting or business travel, such as in-person attendance to meetings, remains restricted at this time, even if paid for by another sponsoring organization.

Exceptions may be made if travel is considered critical to our mission. The potential exceptions to these policies for all caregivers must be discussed with and approved by your respective Executive Team member.

We understand the desire to learn and grow that professional travel allows. Know that we remain committed to opening up more travel opportunities while safeguarding your health and safety.